JP Morgan Upgrades AnaptysBio to Neutral, Lowers Price Target to $30
Portfolio Pulse from richadhand@benzinga.com
JP Morgan analyst Anupam Rama upgrades AnaptysBio (NASDAQ:ANAB) from Underweight to Neutral and lowers the price target from $31 to $30.
May 22, 2023 | 9:08 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AnaptysBio upgraded to Neutral by JP Morgan, with a lowered price target of $30.
JP Morgan's upgrade of AnaptysBio to Neutral from Underweight indicates a more positive outlook on the stock. However, the lowered price target from $31 to $30 suggests a limited upside potential. This mixed signal is likely to result in a neutral short-term impact on ANAB's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100